Welcome to our dedicated page for DBV Technologies S.A. news (Ticker: DBVT), a resource for investors and traders seeking the latest updates and insights on DBV Technologies S.A. stock.
DBV Technologies S.A. (symbol: DBVT) is a clinical-stage specialty biopharmaceutical company revolutionizing the treatment of food allergies, a significant and growing public health issue. Founded in 2002, the company has developed a groundbreaking technology platform known as Viaskin®.
Viaskin® employs epicutaneous immunotherapy (EPIT), a proprietary method that administers allergens through an epicutaneous patch applied to intact skin. This innovative approach targets Langerhans cells, specialized immune cells in the skin, which capture the allergen and migrate to the lymph nodes. This mechanism allows for activation of the immune system without introducing the allergen into the bloodstream, thus minimizing systemic exposure and the risk of severe allergic reactions.
DBV Technologies' flagship product, Viaskin Peanut, is designed for peanut-allergic patients. The patch aims to improve patient tolerability to peanuts and significantly reduce the risk of life-threatening allergic reactions upon accidental exposure. Clinical trials have demonstrated the product's efficacy and safety, making it a promising solution for millions of individuals affected by peanut allergies.
In addition to peanut allergies, DBV Technologies is expanding its portfolio to address other food allergies like milk. The company's robust pipeline and innovative approach position it at the forefront of allergy treatment research.
DBV Technologies has secured multiple worldwide patents for its Viaskin® technology, underlining its pioneering role in the field of immunotherapy. The company continually collaborates with leading research institutions and partners to advance its clinical programs and bring new therapies to market.
Recent achievements include significant milestones in clinical trials, regulatory submissions, and strategic partnerships, reflecting DBV Technologies' commitment to developing safe and effective treatments for food allergies. The company's dedication to addressing unmet medical needs ensures it remains a crucial player in the biopharmaceutical landscape.
DBV Technologies (Nasdaq: DBVT), a clinical-stage biopharmaceutical company, has announced it will host a conference call and live audio webcast on Tuesday, July 30th, at 5:30 p.m. ET to discuss its second quarter 2024 financial results and provide a business update. Interested participants can join the call via teleconference or access the live webcast on the company's website. The event details are as follows:
- Teleconference numbers:
United States: +1-877-346-6112
International: +1-848-280-6350
- Webcast: Available on the Investors & Media section of DBV's website
A replay of the presentation will be accessible on the company's website after the event.
DBV Technologies, a clinical-stage biopharmaceutical company listed on Euronext and Nasdaq under the ticker DBVT, released its half-year report on the liquidity contract with ODDO BHF. As of June 30, 2024, the liquidity account held 303,744 DBV Technologies shares and €62,415.60. This is an increase from the initial assets on July 1, 2018, which included 41,159 shares and €432,367.25. Between January 1, 2024, and June 30, 2024, 912 buy transactions and 694 sales transactions were conducted. The total volumes traded were 299,986 shares and €397,966 for purchases, and 219,230 shares and €310,114 for sales.
DBV Technologies, a clinical-stage biopharmaceutical company, will participate in the Goldman Sachs 45th Annual Global Healthcare Conference. CEO Daniel Tassé will engage in a fireside chat on June 10, 2024, at 8:00 am EDT, and attend one-on-one investor meetings. The company focuses on treating food allergies and other immunologic conditions with significant unmet needs. A live webcast and a 90-day replay of the presentation will be available on DBV Technologies’ Investor Relations website.
As of May 31, 2024, the company reported a total of 96,493,078 shares outstanding. The total number of voting rights is 96,493,078, with a net voting right count of 96,236,383. These figures are in accordance with Article 223-16 of the General Regulations of the Autorité des Marchés Financiers.
DBV Technologies announced a change in the ADS ratio from one ADS for one-half of an ordinary share to one ADS for one ordinary share, effective June 7, 2024. This change will act as a one-for-two reverse ADS split, aiming to regain compliance with Nasdaq's minimum bid price requirement. Registered ADS holders must surrender their certificated ADSs for cancellation and will receive new ADSs in exchange. Uncertificated ADSs will be automatically exchanged. No fractional new ADSs will be issued; instead, they will be aggregated and sold, with proceeds distributed to ADS holders. This change will not affect DBV's underlying ordinary shares.
DBV Technologies, a clinical-stage biopharmaceutical company, announced its participation in the European Academy of Allergy and Clinical Immunology (EAACI) Congress from May 31 to June 3, 2024, in Valencia, Spain. The company will present data on accidental peanut consumption from its EPITOPE Phase 3 study and its ongoing open-label extension study in peanut-allergic toddlers aged 1 to 3 years.
The presentation by Dr. Nicolette Arends will describe the data collection. DBV will also host a symposium moderated by Dr. Stefania Arasi and Dr. Philippe Eigenmann, featuring lectures on the potential clinical applications of epicutaneous immunotherapy. Additionally, DBV will have an exhibit booth to showcase their ongoing clinical trials in peanut-allergic children.
CEO Daniel Tassé emphasized the importance of long-term safety and clinical data, while Chief Medical Officer Pharis Mohideen highlighted the real-world benefits of Viaskin Peanut in reducing allergic reactions over time.
DBV Technologies, a clinical-stage biopharmaceutical company, announced plans to change its American Depositary Shares (ADS) ratio from one ADS to half an ordinary share, to one ADS to one ordinary share. This change, effective June 3, 2024, will act like a one-for-two reverse ADS split, helping the company meet the Nasdaq minimum bid price requirement. Registered ADS holders must surrender their ADSs for cancellation, receiving one new ADS for every two surrendered. Uncertificated ADS holders will see an automatic exchange. The ticker symbol 'DBVT' remains unchanged, and no new ordinary shares will be issued or canceled.
DBV Technologies, a clinical-stage biopharmaceutical company, announced that all resolutions proposed at its 2024 Combined General Meeting were approved by shareholders. The meeting, chaired by Michel de Rosen, took place on May 16, 2024, in Châtillon, France. The resolutions cover various strategic and operational plans aimed at advancing DBV's focus on treatments for food allergies and immunologic conditions with significant unmet needs. Detailed results are available on the company's website.
DBV Technologies, a biopharmaceutical company, will participate in two investor conferences in May 2024. The CEO will present at the Citizens JMP Life Sciences Conference on May 13 and the H.C. Wainwright BioConnect Conference on May 20. The presentations will be available via live webcast on the company's website.
DBV Technologies, a biopharmaceutical company, released its First Quarter 2024 Financial Results and Business Update. The company reported a cash balance of $101.5 million, with VITESSE Phase 3 study enrollment progressing well. Robert Pietrusko was appointed Chief Regulatory Officer. Financially, the company saw a net cash decrease due to operating activities, and faces uncertainties in sustaining operations.
FAQ
What is the current stock price of DBV Technologies S.A. (DBVT)?
What is the market cap of DBV Technologies S.A. (DBVT)?
What does DBV Technologies S.A. specialize in?
What is Viaskin® technology?
What is Viaskin Peanut?
How does Viaskin® technology minimize the risk of allergic reactions?
What other food allergies is DBV Technologies targeting?
When was DBV Technologies founded?
What are some recent achievements of DBV Technologies?
What is the significance of DBV Technologies' patents?
How does DBV Technologies collaborate with other institutions?
What is the financial condition of DBV Technologies?
